Adenovirus-Based Vaccine with Epitopes Incorporated in Novel Fiber Sites to Induce Protective Immunity against Pseudomonas aeruginosa

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Sharma, Anurag ^a   Krause, Anja ^a   Xu, Yaqin ^a   Sung, Biin ^a   Wu, Wendy ^a   Worgall, Stefan ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; OUTER MEMBRANE PROTEIN F; VIRUS FIBER PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNITY; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION;

ADENOVIRIDAE; ANIMALS; ANTIGEN PRESENTATION; CAPSID PROTEINS; EPITOPES; FEMALE; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LUNG; MICE; MODELS, MOLECULAR; PROTEIN STRUCTURE, SECONDARY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; RESPIRATORY MUCOSA;

EID: 84874235491     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056996     Document Type: Article

References (43)

1. Sharma A, Krause A, Worgall S, (2011) Recent developments for Pseudomonas vaccines. Hum Vaccin 7: 999-1011.
2. Doring G, Pier GB, (2008) Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26: 1011-1024.
3. Mutharia LM, Hancock RE, (1983) Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies. Infect Immun 42: 1027-1033.
4. Mutharia LM, Nicas TI, Hancock RE, (1982) Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J Infect Dis 146: 770-779.
5. Gilleland HE Jr, Gilleland LB, Matthews-Greer JM, (1988) Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect Immun 56: 1017-1022.
6. Price BM, Galloway DR, Baker NR, Gilleland LB, Staczek J, et al. (2001) Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infect Immun 69: 3510-3515.
7. Sorichter S, Baumann U, Baumgart A, Walterspacher S, von Specht BU, (2009) Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease. Vaccine 27: 2755-2759.
8. Gilleland LB, Gilleland HE Jr, (1995) Synthetic peptides representing two protective, linear B-cell epitopes of outer membrane protein F of Pseudomonas aeruginosa elicit whole-cell-reactive antibodies that are functionally pseudomonad specific. Infect Immun 63: 2347-2351.
9. Hughes EE, Gilleland LB, Gilleland HE Jr, (1992) Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa. Infect Immun 60: 3497-3503.
10. Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, et al. (2005) Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 115: 1281-1289.
11. Wilson JM, (1996) Adenoviruses as gene-delivery vehicles. N Engl J Med 334: 1185-1187.
12. Lasaro MO, Ertl HC, (2009) New insights on adenovirus as vaccine vectors. Mol Ther 17: 1333-1339.
13. Zaiss AK, Machado HB, Herschman HR, (2009) The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 108: 778-790.
14. Sharma A, Tandon M, Bangari DS, Mittal SK, (2009) Adenoviral vector-based strategies for cancer therapy. Curr Drug ther 4: 117-138.
15. Krause A, Whu WZ, Xu Y, Joh J, Crystal RG, et al. (2011) Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. Vaccine 29: 2131-2139.
16. Worgall S, Krause A, Qiu J, Joh J, Hackett NR, et al. (2007) Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J Virol 81: 13801-13808.
17. Hashimoto M, Boyer JL, Hackett NR, Wilson JM, Crystal RG, (2005) Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun 73: 6885-6891.
18. Ahi YS, Bangari DS, Mittal SK, (2011) Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 11: 307-320.
19. Crompton J, Toogood CI, Wallis N, Hay RT, (1994) Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 75 (Pt 1): 133-139.
20. Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, et al. (2006) Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 80: 5523-5530.
21. Lanzi A, Ben Youssef G, Perricaudet M, Benihoud K, (2011) Anti-adenovirus humoral responses influence on the efficacy of vaccines based on epitope display on adenovirus capsid. Vaccine 29: 1463-1471.
22. Matthews QL, Fatima A, Tang Y, Perry BA, Tsuruta Y, et al. (2010) HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 5: e11815.
23. Matthews QL, (2011) Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm 8: 3-11.
24. Hersh J, Crystal RG, Bewig B, (1995) Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther 2: 124-131.
25. Koizumi N, Mizuguchi H, Sakurai F, Yamaguchi T, Watanabe Y, et al. (2003) Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J Virol 77: 13062-13072.
26. Mittereder N, March KL, Trapnell BC, (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70: 7498-7509.
27. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, et al. (1991) Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 252: 431-434.
28. Song W, Kong HL, Carpenter H, Torii H, Granstein R, et al. (1997) Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 186: 1247-1256.
29. Hicks MJ, De BP, Rosenberg JB, Davidson JT, Moreno AY, et al. (2011) Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther 19: 612-619.
30. Starke JR, Edwards MS, Langston C, Baker CJ, (1987) A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia. Pediatr Res 22: 698-702.
31. Kikuchi T, Hackett NR, Crystal RG, (2001) Cross-strain protection against clinical and laboratory strains of Pseudomonas aeruginosa mediated by dendritic cells genetically modified to express CD40 ligand and pulsed with specific strains of Pseudomonas aeruginosa. Hum Gene Ther 12: 1251-1263.
32. Worgall S, Kikuchi T, Singh R, Martushova K, Lande L, et al. (2001) Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells. Infect Immun 69: 4521-4527.
33. Sharma A, Li X, Bangari DS, Mittal SK, (2009) Adenovirus receptors and their implications in gene delivery. Virus Res 143: 184-194.
34. Xia D, Henry LJ, Gerard RD, Deisenhofer J, (1994) Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 2: 1259-1270.
35. Dunkley ML, Clancy RL, Cripps AW, (1994) A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung. Immunology 83: 362-369.
36. Porwoll JM, Gebel HM, Rodey GE, Markham RB, (1983) In vitro response of human T cells to Pseudomonas aeruginosa. Infect Immun 40: 670-674.
37. Hackett NR, Kaminsky SM, Sondhi D, Crystal RG, (2000) Antivector and antitransgene host responses in gene therapy. Curr Opin Mol Ther 2: 376-382.
38. Yang Y, Li Q, Ertl HC, Wilson JM, (1995) Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 69: 2004-2015.
39. Bangari DS, Mittal SK, (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24: 849-862.
40. Stone D, Lieber A, (2006) New serotypes of adenoviral vectors. Curr Opin Mol Ther 8: 423-431.
41. Sharma A, Bangari DS, Tandon M, Pandey A, HogenEsch H, et al. (2009) Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 386: 44-54.
42. Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, et al. (2001) Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 3: 697-707.
43. Abdel-Motal U, Wang S, Lu S, Wigglesworth K, Galili U, (2006) Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. J Virol 80: 6943-6951.